Fontana L, Meyer TE, Klein S, Holloszy JO
(FDA import alert document placing BPC-157 on detention list.) World Anti-Doping Agency
Some GLP-1 receptor agonists appear capable of entering the brain, which may allow direct neurological effects
Individuals who used GLP-1RAs for 0.5, 1, and 1.5 years had IRRs close to 1.0, with no significant decrease in MACE risk at three years, although these estimates varied across specific treatment strategies defined by prior duration and subsequent exposure patterns
Tamura K, Yamaji T, Yamada T, Ohsawa M, Wakui H
Heres why: Ongoing Absorption Issues: Many people have conditions that impair their ability to absorb B12 from food or oral supplements, such as pernicious anemia or gastrointestinal disorders